ABSTRACT. Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight immature infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. The statement summarizes the indications for surfactant replacement therapy. Because respiratory insufficiency may be a component of multisystem dysfunction in sick infants, surfactant should be administered only at institutions with qualified personnel and facilities for the comprehensive care of sick infants.

Exogenous surfactant replacement has been established as an appropriate preventive and treatment therapy for prematurity-related surfactant deficiency. Surfactant therapy also may be indicated for more mature infants with primary pulmonary hypertension or meconium aspiration syndrome. Single and multicenter randomized controlled trials using synthetic, modified animal, purified animal, and human surfactants have shown that the use of surfactant replacement in preventive or treatment modes has been safe and efficacious. Reduced mortality rates and improved short-term respiratory status for preterm infants with surfactant-deficiency respiratory distress have been confirmed. However, coexistent morbidity, such as necrotizing enterocolitis, nosocomial infections, patent ductus arteriosus, intraventricular hemorrhage, and chronic lung disease, appear primarily unaffected. Reports of long-term outcome for infants enrolled in the randomized surfactant trials and evaluated at 1 to 2 years of age have shown neither beneficial nor adverse effects of surfactant use on growth and/or neurodevelopmental parameters.

Current studies continue to address refinements in surfactant use that may optimize its effectiveness. New products, timing, dosage, methods of administration, and modification for particular gestational age groups are among the issues that may improve the effect of surfactants. Two surfactants, one synthetic and the other modified bovine, have been licensed and are available commercially in the United States.

Universal availability of these products raises the concern that surfactants may be used to address the respiratory component of multisystem disorders that affect high-risk, low birth weight infants when other diseases cannot be addressed appropriately. This is a critical issue because the target population for surfactant therapy is primarily the high-risk, low birth weight infants who may have multisystem disorders that are not affected beneficially by treatment with surfactants. Caring for these infants in nurseries without the full range of capabilities required may affect the overall outcome adversely.

As systems of neonatal health care adapt to modified patterns of disease in low birth weight infants, the following recommendations should be incorporated.

RECOMMENDATIONS

1. Surfactant replacement therapy should be directed by physicians qualified and trained in its use and administration. Qualifications should include experience in management of the respiratory care of low birth weight infants, particularly those on mechanical ventilation.

2. Nursing and respiratory therapy personnel experienced in the management of low birth weight infants, including mechanical ventilation, should be available within the unit at the bedside when surfactant therapy is administered.

3. Equipment necessary for managing and monitoring the condition of low birth weight infants, including that needed for mechanical ventilation, should be available on-site when surfactant therapy is administered. Radiology and laboratory support to manage a broad range of needs of these infants should be available.

4. More important, surfactant therapy should be used only in institutions in which facilities and personnel are available for the management of multisystem disorders and low birth weight infants.

5. An institutionally approved surfactant therapy protocol, which is a mandatory component of the quality assurance program for neonates, should exist.

6. In the institutions not satisfying recommendations 2 through 5, and when timely transfer to an appropriate institution cannot be achieved, surfactant therapy may be given, but only by a physician skilled in endotracheal intubation. Under these circumstances, consultation with a subspecialty center should be obtained. Infants should be transferred from such institutions if appropriate and when feasible to a center with appropriate facilities and staff trained to care for multisystem morbidity in low birth weight infants.
Committee on Fetus and Newborn, 1998–1999
James A. Lemons, MD, Chairperson
Lillian R. Blackmon, MD
William P. Kanto, Jr, MD
Hugh M. MacDonald, MD
Carol A. Miller, MD
Lu-Ann Papile, MD
Warren Rosenfeld, MD
Craig T. Shoemaker, MD
Michael E. Speer, MD

Liaison Representatives
Michael F. Greene, MD
American College of Obstetricians and Gynecologists
Patricia Johnson, RN, MS, NNP
American Nurses Association, Association of Women’s Health, Obstetric and Neonatal Nurses, National Association of Neonatal Nurses
Douglas D. McMillan, MD
Canadian Paediatric Society
Solomon Iyasu, MBBS, MPH
Centers for Disease Control and Prevention
Linda L. Wright, MD
National Institutes of Health

Section Liaisons
Richard Molteni, MD
Section on Perinatal Pediatrics
Jacob C. Langer, MD
Section on Surgery

Consultants
Marilyn Escobedo, MD
Avroy Fanaroﬀ, MD

References


American Academy of Pediatrics

Downloaded from by guest on September 12, 2017
Surfactant Replacement Therapy for Respiratory Distress Syndrome
Committee on Fetus and Newborn

*Pediatrics* 1999;103;684
DOI: 10.1542/peds.103.3.684

The online version of this article, along with updated information and services, is located on the World Wide Web at:

/content/103/3/684.full.html